Evogene Ltd. (NASDAQ:EVGN) Q3 2023 Earnings Call Transcript

I think this is part from Evogene capabilities in the field of gene editing. In the past we were leading the biggest consortium here in Israel in the field of gene editing. And I think that Evogene has some unique capabilities in this field that we can use to help other companies to improve different traits in different organisms. But at least for now, we don’t see it evolving to a separate entity.

Benjamin Haynor: Okay, great. Well, thanks for taking the questions, gentlemen. That’s all I have.

Ofer Haviv: Thank you.

Amit Noam: Thank you.

Operator: [Operator Instructions] This concludes the question-and-answer session. Before I ask Mr. Ofer Haviv to go ahead with his closing statement, I would like to remind participants that a replay of this call is scheduled to begin two hours after the conference in the U.S., please call 1-888-326-9310, in Israel, please call 03-9255-901 Internationally please call 9723-9255-901. Mr. Haviv, would you like to make your concluding statement?

Ofer Haviv: Yes. Thanks you all for joining the call today. We look forward to updating you with our progress on our next call. Thank you once again.

Operator: Thank you. This concludes Evogene’s third quarter 2023 results conference call. Thank you for your participation. You may go ahead and disconnect.